Clinical trial
A Trial of Antigen-specific Immune Tolerance Induction in Mucopolysaccharidosis I (MPS I) Patients Initiating Enzyme Replacement Therapy With Aldurazyme® (Laronidase)
NCT00741338 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Trial of Antigen-specific Immune Tolerance Induction in Mucopolysaccharidosis I (MPS I) Patients Initiating Enzyme Replacement Therapy With Aldurazyme® (Laronidase)
- Lead sponsor
- Genzyme, a Sanofi Company
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- September 30, 2008
- Completion date
- September 30, 2012
- Enrollment
- 7 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.